Sector News

Axovant buys more gene therapies, setting it up for a busy 2019

December 14, 2018
Life sciences

Axovant has licensed two gene therapies from the University of Massachusetts Medical School (UMMS). The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic.

Following the failures of intepirdine and nelotanserin, Axovant purged its pipeline of small molecules and set out to buy a roster of gene therapies. The pivot got underway with a deal for clinical-phase Parkinson’s disease gene therapy AXO-Lenti-PD in June and continued with the licensing of a gene therapy treatment for oculopharyngeal muscular dystrophy (OPMD) the following month.

While the OPMD gene therapy is due to enter human testing next year, the pivot nonetheless left Axovant’s clinical pipeline looking a little light. The latest gene therapy deal goes some way toward addressing that issue.

Axovant is paying UMMS $10 million upfront for the rights to two gene therapies designed to treat GM1 and GM2 gangliosidosis, lysosomal storage disorders that cause the potentially fatal build up of toxic gangliosides. The deal commits Axovant to up to $24.5 million in development and regulatory milestones, plus up to $39.8 million in commercial milestones and tiered mid-single-digit royalties.

The more advanced of the two gene therapies, AXO-AAV-GM2, is already in clinical development in patients with GM2 gangliosidosis, a group of rare disorders also known as Tay-Sachs and Sandhoff diseases. Axovant expects to have data from the trial in the first quarter of next year.

UMMS’ other gene therapy, AXO-AAV-GM1, is due to move into the clinic in the first half of next year. The trial will be conducted at the NIH, which has accrued a repository of natural history data on the diseases Axovant thinks it could use as a control in registrational studies. Axovant expects to have initial data from the GM1 trial in the second half of next year.

The addition of two clinical readouts to Axovant’s schedule for 2019 means the company’s calendar is now fairly well stocked with potentially business boosting events. Axovant’s other big moment will come in March, when it is due to release clinical data on its Parkinson’s gene therapy.

With clinical trial activity ramping up again, Axovant is making a public offering of its stock. At the time of writing, Axovant is yet to say how much it hopes to raise, but the shelf registration covering the offering permits the sale of up to $750 million in stock. Axovant ended September with $91 million in cash, having run up operating expenses of $81 million over the first six months of the year.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach